These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 2381986)

  • 1. Lymphocytes of healthy subjects and schizophrenic patients possess no high-affinity binding sites for spiroperidol.
    Rao ML; Deister A; Roth A
    Pharmacopsychiatry; 1990 Jul; 23(4):176-81. PubMed ID: 2381986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinctions between ligand-binding sites for [3H]dopamine and D2 dopaminergic receptors characterized with [3H]spiroperidol.
    Hancock AA; Marsh CL
    Mol Pharmacol; 1984 Nov; 26(3):439-51. PubMed ID: 6238230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thermodynamic differences between agonist and antagonist interactions with binding sites for [3H]spiroperidol in rat striatum.
    Zahniser NR; Molinoff PB
    Mol Pharmacol; 1983 Mar; 23(2):303-9. PubMed ID: 6835199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [3H]Ro 22-1319 (piquindone) binds to the D2 dopaminergic receptor subtype in a sodium-dependent manner.
    Nakajima T; Iwata K
    Mol Pharmacol; 1984 Nov; 26(3):430-8. PubMed ID: 6149457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction of [3H]spiperone with rat striatal dopamine D-2 receptors: kinetic evidence for antagonist-induced formation of ternary complex.
    Chatterjee TK; Scott CE; Vazquez DM; Bhatnagar RK
    Mol Pharmacol; 1988 Apr; 33(4):402-13. PubMed ID: 3357484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effect of in vitro serotonin on dopaminergic binding sites in rat striatal membranes].
    Oelssner W; Raubach KH; Oelssner W
    Biomed Biochim Acta; 1983; 42(7-8):931-6. PubMed ID: 6651809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimation of the apparent affinity of the striatal dopamine receptors for the radioligand[3H]spiperone [( 3H]spiroperidol).
    Hruska RE
    J Neurosci Res; 1984; 12(4):571-81. PubMed ID: 6512888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Dopaminergic receptors on lymphocytes in idiopathic Parkinson's disease (author's transl)].
    Le Fur G; Meininger V; Baulac M; Phan T; Uzan A
    Rev Neurol (Paris); 1981; 137(2):89-96. PubMed ID: 7244495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of the bovine striatal D2 receptor, but not the D1 receptor, in bovine adrenal medulla.
    Maroto R; López MG; del Valle M; Naranjo JR; Mellström B; García AG
    Mol Pharmacol; 1995 Jan; 47(1):40-50. PubMed ID: 7838132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lymphocyte 3H-spiroperidol binding in schizophrenia: preliminary findings.
    Rotstein E; Mishra RK; Singal DP; Barone D
    Prog Neuropsychopharmacol Biol Psychiatry; 1983; 7(4-6):729-32. PubMed ID: 6686701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 3H-spiroperidol binding sites in blood platelets.
    Khanna AS; Agrawal AK; Seth PK
    Biochem Biophys Res Commun; 1987 Aug; 146(3):983-8. PubMed ID: 3619946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Organization of dopamine D1 and D2 receptors in human striatum: receptor autoradiographic studies in Huntington's disease and schizophrenia.
    Joyce JN; Lexow N; Bird E; Winokur A
    Synapse; 1988; 2(5):546-57. PubMed ID: 2973147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemical modification reveals involvement of tyrosine in ligand binding to dopamine D1 and D2 receptors.
    Srivastava LK; Mishra RK
    Biochem Int; 1990; 21(4):705-14. PubMed ID: 2241996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cerebellar and striatal dopamine receptors: effects of reeler and weaver murine mutations.
    Panagopoulos NT; Matsokis NA; Valcana T
    J Neurosci Res; 1993 Aug; 35(5):499-506. PubMed ID: 8377223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of membrane-bound and soluble D2 receptors in canine caudate using [125I]IBZM.
    Schonwetter BS; Luedtke RR; Kung MP; Billings J; Kung HF; Molinoff PB
    J Pharmacol Exp Ther; 1989 Jul; 250(1):110-6. PubMed ID: 2526213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [3H]mazindol binding associated with neuronal dopamine and norepinephrine uptake sites.
    Javitch JA; Blaustein RO; Snyder SH
    Mol Pharmacol; 1984 Jul; 26(1):35-44. PubMed ID: 6087116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Association between uptake to lymphocytes from schizophrenic patients and therapeutic efficacy].
    Shimogawa S; Kaku H; Yoshimoto S; Nakane Y
    Yakubutsu Seishin Kodo; 1986 Jun; 6(2):239-46. PubMed ID: 2877529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interactions of dopaminergic agonists and antagonists with dopaminergic D3 binding sites in rat striatum. Evidence that [3H]dopamine can label a high affinity agonist-binding state of the D1 dopamine receptor.
    Leff SE; Creese I
    Mol Pharmacol; 1985 Feb; 27(2):184-92. PubMed ID: 3969067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative analysis of the interaction of [3H]spiroperidol with serotonin and dopamine receptors.
    McGonigle P
    J Cardiovasc Pharmacol; 1988; 11 Suppl 1():S73-7. PubMed ID: 2459520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of dopamine receptor sites labeled by [3H]-S-sulpiride and [3H]-spiperone in striatum.
    Zahniser NR; Dubocovich ML
    J Pharmacol Exp Ther; 1983 Dec; 227(3):592-9. PubMed ID: 6655559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.